Literature DB >> 1500249

Alopecia universalis treated with oral cyclosporine A and prednisolone: immunologic studies.

H Teshima1, A Urabe, M Irie, T Nakagawa, J Nakayama, Y Hori.   

Abstract

Alopecia universalis is a refractory condition. Although the cause of this disease is unknown, immunologic abnormalities have recently been suspected. Thus, we treated six cases of refractory alopecia universalis with immunotherapy. Oral administration of cyclosporine A (2.5 mg/kg) and prednisolone (5 mg/day) resulted in marked symptomatic improvement. Cyclosporine A did not produce any side effects because the administered dosage was relatively low. At present, more than 6 months after the cessation of treatment, recurrence of alopecia has not been seen. Oral administration of low-dose cyclosporine A and prednisolone is considered to be an effective treatment for this disease. Immunologic examination of peripheral blood demonstrated improvement of immunologic function. In particular, CD8-positive T cells, NK cells, and C3, which had been reduced, were increased. A reduction in active CD4 cells, eosinophils, and circulating immune complexes was observed. Histology with fluorescent antibodies showed T-cell infiltration around the hair matrixes. This phenomenon was no longer observed after treatment. These improvements in immunologic function were seen in parallel with the resolution of the clinical symptoms, indicating that immunologic abnormalities are related to this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1500249     DOI: 10.1111/j.1365-4362.1992.tb02706.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  5 in total

1.  Three cases of alopecia following clinical islet transplantation.

Authors:  D M Zuk; A Koh; S Imes; A M J Shapiro; P A Senior
Journal:  Am J Transplant       Date:  2011-01       Impact factor: 8.086

2.  Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids.

Authors:  Deborah Lee; Doo Jin Oh; Jung Wook Kim; Sung Wook Park; Min Kyung Oh; Ho Suk Sung; Seon Wook Hwang
Journal:  Ann Dermatol       Date:  2008-12-31       Impact factor: 1.444

Review 3.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata.

Authors:  In Kwon Yeo; Eun Jung Ko; Yeon A No; Ee Seok Lim; Kui Young Park; Kapsok Li; Beom Joon Kim; Seong Jun Seo; Myeung Nam Kim; Chang Kwun Hong
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

Review 5.  Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic Review.

Authors:  Joanna Nowaczyk; Karolina Makowska; Adriana Rakowska; Mariusz Sikora; Lidia Rudnicka
Journal:  Dermatol Ther (Heidelb)       Date:  2020-04-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.